Dara L. Aisner
University of Colorado Denver
178 Papers
470 Citations
Dara L. Aisner is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 53, co-authored 148 publications. Previous affiliations of Dara L. Aisner include National Institutes of Health & University of Texas at Dallas.
Chat about Author
Papers
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology
David S. Ettinger,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Lucian R. Chirieac,Thomas A. D'Amico,Malcolm M. DeCamp,Thomas J. Dilling,Michael C. Dobelbower,Robert C. Doebele,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Ritsuko Komaki,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Leah J. Leisch,Rogerio Lilenbaum,Jules Lin,Billy W. Loo,Renato Martins,Gregory A. Otterson,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +34 more
TL;DR: This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastasis disease.
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele,Amanda B. Pilling,Dara L. Aisner,Tatiana G. Kutateladze,Anh T. Le,Andrew Weickhardt,Kimi L. Kondo,Derek J. Linderman,Lynn E. Heasley,Wilbur A. Franklin,Marileila Varella-Garcia,D. Ross Camidge +11 more
TL;DR: Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of separate oncogenic drivers.
1.1K
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S. Ettinger,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Ankit Bharat,Debora S. Bruno,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D'Amico,Malcolm M. DeCamp,Thomas J. Dilling,Jonathan E. Dowell,Scott N. Gettinger,Travis E. Grotz,Matthew A. Gubens,Aparna Hegde,Rudy P. Lackner,Michael Lanuti,Jules Lin,Billy W. Loo,Christine M. Lovly,Fabien Maldonado,Erminia Massarelli,Daniel Morgensztern,Thomas Ng,Gregory A. Otterson,Jose M. Pacheco,Sandip Pravin Patel,Gregory J. Riely,Jonathan W. Riess,Steven E. Schild,Theresa A. Shapiro,Aditi P. Singh,James P. Stevenson,Alda L. Tam,Tawee Tanvetyanon,Jane Yanagawa,Stephen C. Yang,Edwin Yau,Kristina M. Gregory,Miranda Hughes +41 more
TL;DR: Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer, and this selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastasis NSLI and actionable mutations.
1K
Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines
David S. Ettinger,Douglas E. Wood,Charu Aggarwal,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Ankit Bharat,Debora S. Bruno,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D'Amico,Thomas J. Dilling,Michael C. Dobelbower,Scott N. Gettinger,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Jules Lin,Billy W. Loo,Renato Martins,Gregory A. Otterson,Sandip Pravin Patel,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +35 more
TL;DR: The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) as discussed by the authors address all aspects of management for NSCLC, focusing on recent updates in immunotherapy.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
David S. Ettinger,David S. Ettinger,Douglas E. Wood,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Wallace Akerley,Jessica Bauman,Jessica Bauman,Ankit Bharat,Ankit Bharat,Debora S. Bruno,Debora S. Bruno,Joe Y. Chang,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D'Amico,Thomas J. Dilling,Thomas J. Dilling,Jonathan E. Dowell,Scott N. Gettinger,Matthew A. Gubens,Aparna Hegde,Mark Hennon,Mark Hennon,Rudy P. Lackner,Michael Lanuti,Michael Lanuti,Ticiana A. Leal,Ticiana A. Leal,Jules Lin,Jules Lin,Billy W. Loo,Christine M. Lovly,Christine M. Lovly,Renato Martins,Renato Martins,Erminia Massarelli,Erminia Massarelli,Daniel Morgensztern,Daniel Morgensztern,Thomas Ng,Thomas Ng,Gregory A. Otterson,Gregory A. Otterson,Sandip P. Patel,Sandip P. Patel,Gregory J. Riely,Gregory J. Riely,Steven E. Schild,Steven E. Schild,Theresa A. Shapiro,Theresa A. Shapiro,Aditi P. Singh,Aditi P. Singh,James P. Stevenson,James P. Stevenson,Alda Tam,Alda Tam,Jane Yanagawa,Jane Yanagawa,Stephen C. Yang,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +64 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC as mentioned in this paper.